Precigen, Inc. (NASDAQ:PGEN) Receives $6.33 Average Price Target from Analysts

Precigen, Inc. (NASDAQ:PGEN) has been assigned an average rating of “Moderate Buy” from the five research firms that are covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating and four have given a buy rating to the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $6.33.

Several research firms have commented on PGEN. HC Wainwright reaffirmed a “buy” rating and issued a $4.00 target price on shares of Precigen in a research note on Friday, November 15th. JMP Securities restated a “market outperform” rating and issued a $5.00 target price on shares of Precigen in a research note on Tuesday, January 14th.

Precigen Stock Down 4.2 %

Shares of PGEN opened at $1.13 on Monday. Precigen has a 52-week low of $0.65 and a 52-week high of $1.93. The company has a market capitalization of $330.94 million, a PE ratio of -2.05 and a beta of 1.65. The company has a 50-day simple moving average of $0.92 and a 200-day simple moving average of $1.06.

Institutional Trading of Precigen

A number of large investors have recently bought and sold shares of the stock. Bank of New York Mellon Corp grew its stake in Precigen by 4.8% during the second quarter. Bank of New York Mellon Corp now owns 421,788 shares of the biotechnology company’s stock worth $666,000 after buying an additional 19,301 shares during the last quarter. Renaissance Technologies LLC grew its holdings in Precigen by 12.4% during the 2nd quarter. Renaissance Technologies LLC now owns 1,182,690 shares of the biotechnology company’s stock worth $1,869,000 after acquiring an additional 130,500 shares during the last quarter. AQR Capital Management LLC grew its stake in shares of Precigen by 56.7% during the second quarter. AQR Capital Management LLC now owns 50,002 shares of the biotechnology company’s stock valued at $79,000 after purchasing an additional 18,097 shares during the last quarter. The Manufacturers Life Insurance Company boosted its position in Precigen by 40.7% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 56,998 shares of the biotechnology company’s stock valued at $90,000 after buying an additional 16,486 shares during the last quarter. Finally, SG Americas Securities LLC boosted its position in Precigen by 44.2% in the 3rd quarter. SG Americas Securities LLC now owns 45,063 shares of the biotechnology company’s stock valued at $43,000 after buying an additional 13,823 shares during the last quarter. 33.51% of the stock is currently owned by institutional investors.

Precigen Company Profile

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.